COMMUNIQUÉS West-GlobeNewswire

TECregen Strengthens Management Team and Board to Advance Thymus Regeneration and Lead Program TEC001
10/11/2026
Elisabeth Svanberg, MD, PhD, appointed Chief Medical Officer, adding extensive global clinical-development and regulatory expertise Thomas Hanke, PhD, joins the Board, bringing more than 30 years of immunology, drug- [...]
CVMP adopts a positive opinion for SCOVELLA®, the first therapy for hyperinsulinaemia in horses with Equine Metabolic Syndrome
10/11/2026
SCOVELLA ® was developed to reduce hyperinsulinaemia in insulin-dysregulated horses, a key underlying driver of laminitis – a common, painful inflammatory condition in horses’ hooves and significant unmet need in equine [...]
Disclosure of the Total Number of Voting Rights and Shares Forming the Share Capital
10/11/2026
NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL DISCLOSURE OF THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL Article 223-16 du Règlement général de l’Autorité des Marchés [...]
Nombre d’actions et de droits de vote composant le capital social
10/11/2026
NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL DISCLOSURE OF THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL Article 223-16 du Règlement général de l’Autorité des Marchés [...]
UsAgainstAlzheimer’s Names Danielle Carnival, Ph.D., Chief Executive Officer; Co-Founder George Vradenburg Continues as Executive Chairman
10/11/2026
Appointment builds on momentum and urgency in the fight to end Alzheimer’s WASHINGTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s (UsA2) today announced the appointment of Danielle Carnival, Ph.D., as Chief [...]
Australian ALS therapy aimed at halting disease progression and restoring function advances to Phase 2 trial
10/11/2026
Video interviews, overlay and photos here BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- An Australian-developed therapy aimed at halting the progression of amyotrophic lateral sclerosis (ALS) and restoring [...]
Dimora Medical Supports Empower HS 2026, Advancing Everyday Wound Care for the HS Community
10/11/2026
Silicone foam dressings featuring MegaSorb™ technology were included in attendee gift bags to support at-home management of exuding wounds New York, USA, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Dimora Medical, a pioneer in [...]
Australian therapy aimed at halting MND progression and restoring function advances to national Phase 2 trial
10/11/2026
Video interviews, overlay and photos here BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- An Australian-developed therapy aimed at halting the progression of motor neurone disease (MND) and restoring function by [...]
Valneva annonce un taux de séroréponse de 94% cinq ans après une dose unique du vaccin contre le chikungunya IXCHIQ®
10/11/2026
94% des participants ont maintenu une séroréponse cinq ans après une dose unique du vaccin La persistance des anticorps chez les adultes âgés de 65 ans et plus est comparable à celle des jeunes adultes Ces données [...]
Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
10/11/2026
94% of participants maintained seroresponse five years after a single vaccination Comparable antibody persistence observed in older (65+) and younger adults Data further reinforce IXCHIQ ® 's differentiated profile with [...]
Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026
10/11/2026
Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers Phase III PrevenTRON study design specifics for trontinemab in preclinical [...]
Trogenix appoints industry veterans John Young as Chair and Josh Murray as Non-Executive Director to support global strategy, commercial foundation and patient access
10/11/2026
John brings more than 35 years of operational and commercial leadership with extensive experience in bringing medicines to market at global scale Josh brings deep capital markets and strategic experience to support the [...]
TME Pharma fournit davantage de détails sur l'accord de négociation exclusif conclu avec TMS Co., Ltd. concernant le NOX-A12
10/11/2026
TME Pharma fournit davantage de détails sur l'accord de négociation exclusif conclu avec TMS Co., Ltd. concernant le NOX-A12 Berlin, Allemagne, le 10 novembre 2026, 8h30 CET – TME Pharma N.V. (Euronext Growth Paris: [...]
TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12
10/11/2026
TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12 Berlin, Germany, November 10, 2026, 8.30 am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech- [...]
IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
09/11/2026
NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious [...]
SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.
09/11/2026
Concludes 30-Year Tenure Leading Development of TPOXX®, the First FDA-Approved Antiviral for the Treatment of Smallpox NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies (NASDAQ: SIGA), a commercial stage [...]
MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
09/11/2026
Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track [...]
POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
09/11/2026
TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Xenon Reports Q3 2026 Financial Results and Provides Business Update
09/11/2026
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies [...]

Pages